Effects of piogilitazone on diabetes-related outcomes in Hispanic patients

American Journal of Health-System Pharmacy

Volumn 60, Issue 5, 2003, Pages 469-473

  Jun, Jeany Kim ^a,b   Gong, William C ^b,c   Mathur, Ruchi ^d  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; GLIBENCLAMIDE PLUS METFORMIN; INSULIN; METFORMIN; PIOGLITAZONE; SULFONYLUREA DERIVATIVE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THIAZOLE DERIVATIVE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES CONTROL; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ETHNIC GROUP; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT OUTCOME; UNITED STATES; WEIGHT GAIN; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; COMPARATIVE STUDY; ETHNOLOGY; GLUCOSE BLOOD LEVEL; HISPANIC; MIDDLE AGED; TIME;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; HISPANIC AMERICANS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THIAZOLES; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; UNITED STATES;

EID: 0037639810     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/60.5.469     Document Type: Article

References (23)

1. Reents S, ed. Clinical pharmacology 2000 [CD ROM]. Tampa, FL: Gold Standard Media; 2002.
2. Boyle PJ, King AB, Olansky L et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther. 2002; 24:378-96.
3. U.S. Bureau of the Census. The Hispanic population in the United States. www. census.gov/population/cen2000/phc-t10/tab01-00.pdf (accessed 2002 May 17).
4. Stern MP, Braxton DM. Diabetes in Hispanic Americans. In: Harris MI, ed. Diabetes in America. 2nd ed. Bethesda, MD: National Institutes of Health; 1995:631-56.
5. Actos (pioglitazone) package insert. Lincolnshire, IL: Takeda Pharmaceuticals America; 1999 Jul.
6. Mudaliar S, Henry RR. New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu Rev Med. 2001; 52: 239-57.
7. American Diabetes Association. Standards of medical care for patients with diabetes mellitus (position statement). Diabetes Care. 2002; 25(suppl 1): S33-49.
8. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33. Lancet. 1998; 352:837-53.
9. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321:405-12.
10. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2002; 25(suppl 1): S71-3.
11. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002; 287:356-9.
12. Isomaa BO, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001; 14:683-9.
13. Nass CM, Blumenthal RS. Glitazones and the potential improvement of lipid profiles in diabetes patients at high risk for cardiovascular disease. Am J Manag Care. 2000; 6:S1247-56.
14. National Heart, Lung, and Blood Institute. Third report of the National Cholesterol Education Program (NCEP) Expert Panel. Washington, DC: U.S. Department of Health and Human Services, 2001; NIH publication no. 01-3670.
15. Lefebvre AM, Peinado-Onsurbe J, Leiterscorf I et al. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. Arterioscler Thromb Vasc Biol. 1997; 17:1756-64.
16. Khan MA, St. Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care. 2002; 25:708-11.
17. Einhorn D, Rendell M, Rosenzweig J et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther. 2000; 22:1395-409.
18. Aronoff S, Rosenblatt S, Braithwaite S et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care. 2000; 23:1605-11.
19. Parulkar AA, Pendergrass ML, Granda-Ayala R et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med. 2001; 134:61-71.
20. O'Moore-Sullivan TM, Prins JB. Thiazolidinediones and type 2 diabetes: new drugs for an old disease. Med J Aust. 2002; 176:381-6.
21. Krische D. The glitazones: proceed with caution. West J Med. 2000; 173:54-7.
22. Valve R, Sivenius K, Miettinen J et al. Two polymorphisms in the peroxisome proliferator-activated receptor-γ gene are associated with severe overweight among obese women. J Clin Endocrinol Metab. 1999; 84:3708-12.
23. Mavandadi A, Gong WC. Effects of troglitazone in Hispanic patients with type 2 diabetes mellitus. Curr Ther Res. 1999; 60: 494-501.